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Abstract
Objective: The primary objective was to assess the effect of MVC intensification on latently infected CD4+ T cells in
chronically HIV-1-infected patients receiving antiretroviral therapy.
Methods: We performed an open-label pilot phase II clinical trial involving chronically HIV-1-infected patients receiving
stable antiretroviral therapy whose regimen was intensified with 48 weeks of maraviroc therapy. We analyzed the latent
reservoir, the residual viremia and episomal 2LTR DNA to examine the relationship between these measures and the HIV-1
latent reservoir, immune activation, lymphocyte subsets (including effector and central memory T cells), and markers
associated with bacterial translocation.
Results: Overall a non significant reduction in the size of the latent reservoir was found (p = 0.068). A mean reduction of 1.82
IUPM was observed in 4 patients with detectable latent reservoir at baseline after 48 weeks of intensification. No effect on
plasma residual viremia was observed. Unexpectedly, all the patients had detectable 2LTR DNA circles at week 24, while
none of them showed those circles at the end of the study. No changes were detected in CD4+ or CD8+ counts, although a
significant decrease was found in the proportion of HLA-DR+/CD38+ CD4+ and CD8+ T-cells. LPS and sCD14 levels increased.
Conclusions: Intensification with MVC was associated with a trend to a decrease in the size of the latent HIV-1 reservoir in
memory T cells. No impact on residual viremia was detected. Additional studies with larger samples are needed to confirm
the results.
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Introduction
Antiretroviral therapy (ART) can reduce plasma HIV-1 RNA
levels to ,50 copies/ml [1]. However, low residual viremia, which
is only detectable using ultrasensitive assays, can persist despite
ART [2–4]. The origin and clinical implications of persistent low-
level viremia are uncertain. While some studies postulate that it
may be the result of virus released from latently infected cells [5–
7], others support that it could arise from ongoing viral replication,
as a consequence of incomplete inhibitory activity or penetration
of antiretroviral drugs [8–13].
Although intensification of current ART with potent drugs
could potentially decrease residual viremia and prevent replen-
ishment of viral reservoirs, prior intensification studies have not
demonstrated any impact on residual viremia [12,14–17]. Only
one study confirmed a transient increase in episomal 2LTR DNA
circles after raltegravir intensification [18] as an indicator of recent
HIV-1 replication [19–21], and another study showed a decrease
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in the frequency of episodes of intermittent viremia [22]. To our
knowlegede, only a few studies have previously evaluated the effect
of intensification of stable therapy on the latent reservoir of resting
CD4+ T cells in chronically HIV-1-infected patients with
controversial results. Ramratnam et al. found an accelerated
decay of the HIV-1 latent reservoir after intensification therapy
with abacavir with or without efavirenz [22]. Two more studies
that measured the impact on the CD4+ T cell reservoir in patients
receiving a four-drug combination as initial antiretroviral therapy
provided discordant results, namely, a reduction in the reservoir in
patients treated during acute infection [23] and no changes in
chronically infected patients [24].
Bacterial translocation and a low level of ongoing viral
replication have been associated with an increase in immune
activation in HIV-1-infected patients [25,26]. Evidence of
increased bacterial translocation from damaged intestinal tissue
was recently demonstrated in chronic HIV-1 infection [25,27]. In
acute HIV-1 infection, intestinal CD4+ T cells are rapidly depleted
and T-cell activation is high. Since monitoring intestinal cells is
difficult, expression of surrogate markers such as the mucosal
homing receptor a4b7 integrin on circulating T cells has been
proposed to correlate with loss or restoration of intestinal CD4+ T
cells and could prove helpful in monitoring the success of
therapeutic strategies [28–30]. Besides, recent studies have shown
that HIV-1 utilizes a4b7 integrin to bind to CD4+ T cells [31].
Maraviroc (MVC) is a potent new antiretroviral agent approved
for the treatment of HIV-1 infection that blocks interaction
between the virus and the CCR5 co-receptor, a crucial step in the
HIV-1 life cycle [32]. Previous clinical trials have demonstrated
the safety, tolerability, and efficacy of MVC in both treatment-
naive and treatment-experienced patients [33,34].
We performed a prospective open-label pilot phase II clinical
trial to assess the effect of MVC intensification on latently infected
CD4+ T cells in chronically HIV-1-infected patients receiving
antiretroviral therapy. We also analyzed residual viremia and
episomal 2LTR DNA to examine the relationship between these
measures and the HIV-1 latent reservoir, immune activation,
lymphocyte subsets (including effector and central memory T
cells), and markers associated with bacterial translocation. The
hypothesis was that if these factors are causally linked, altering one
of them with the intervention should result in alteration of the
others.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study Design
We performed an open-label pilot phase II clinical trial to
evaluate the effect of MVC on the cellular HIV-1 reservoir in
patients receiving ART. The study was conducted at Hospital
Universitario Ramo´n y Cajal in Madrid, Spain between 2008 and
2010. This independent clinical trial (NCT00795444) had a follow
up of 48 weeks of intensification with MVC (developed and
provided by Pfizer, Inc.).
Ethics Statement
The study was carried out according to the recommendations of
the Declaration of Helsinki and current Spanish legislation on
clinical trials. It was approved by the AEMPS (Spanish Agency for
Medications and Health Products) and our Independent Ethics
Committee (Hospital Ramo´n y Cajal, 28034 Madrid, Spain;
ceic.hrc@salud.madrid.org). All patients provided their written
informed consent for participation, which included sample
collection and laboratory determinations.
Patients and specimen collection
Nine patients met all the following inclusion criteria: undetect-
able plasma viral load (pVL) by standard commercial assays (,50
copies HIV-1 RNA/ml) for at least two years; ART with three or
more drugs for at least two years; CD4+ T lymphocyte count .
350 cells/mm3; R5 viral tropism testing a pretreatment sample
using a phenotypic assay (TrofileH, Monogram Biosciences, C.A),
and no previous treatment with MVC. Patients were recruited
from two hospitals (Hospital Ramo´n y Cajal and Hospital Doce de
Octubre), both in Madrid, Spain.
Patient’s enrollment, allocation and follow up are described in
figure 1.
Samples were collected at baseline and after 12, 24, 36, and 48
weeks of intensification with MVC. A total of 300 ml of
heparinized whole blood was drawn to quantify the latent HIV-
1 reservoir; 50 ml of whole blood with EDTA was drawn to obtain
plasma and isolate peripheral blood mononuclear cells (PBMC).
Samples were cryopreserved in the HIV Biobank of the Spanish
AIDS Research Network (RIS) following current procedures [35].
Figure 1. Consort Flow Diagram.
doi:10.1371/journal.pone.0027864.g001
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In addition, two control groups (10 treatment-naive HIV-1-
infected patients, and 10 HIV-1-negative subjects) were also
analyzed for some measurements.
Latently HIV-1-infected memory T cells
Two baseline determinations (three months apart) were
performed to investigate the accuracy of the method and the
stability of the reservoir.
We carried out a previously described co-culture assay [36,37].
Briefly, PBMC were isolated from 300 ml of heparinized whole
blood using Ficoll density gradient centrifugation (Lymphocytes
Isolation Solution, Rafer, S.L Zaragoza, Spain). Resting CD4+ T
cells (CD4+/HLA-DR-/CD25-) were isolated and purified using
magnetic beads according to the manufacturer’s recommendations
(Miltenyi Biotec, S.L. Bergisch Gladbach, Germany). CD4+ T-cell
purity greater than 99% with less than 0.4% activation was
confirmed by flow cytometry. The isolated resting CD4+ T cells
were plated in replicate limiting dilutions and co-cultured with
allogenic irradiated PBMC from seronegative donors and
phytohemagglutinin. The activated cell culture was fed once a
week with PBMC from healthy donors after depletion of CD8+ T
cells. On days 15 and 21, culture supernatants were tested for
HIV-1 replication using the HIV-1 p24 antigen assay (Innoge-
netics Diagnostica Iberia, S.L Tarragona, Barcelona, Spain).
Infected cell frequencies were determined by the maximum
likelihood method and expressed as infectious units per million
(IUPM) resting CD4+ T cells [38]. The millions of purified resting
CD4+ T cells obtained from the total PBMCs conditioned the
number of replicates of each dilution. The assay was performed to
each point as duplicate fivefold dilution series.
From baseline to week 12 of follow-up, the limit of detection of
the assay was 0.12 IUPM resting CD4+ T cells. Thereafter, the
limit of detection decreased to 0.023 IUPM, since the total blood
extraction volume was increased after approval of the amended
protocol by the IEC.
Residual viremia
Residual viremia was measured with internally controlled an
ultrasensitive quantitative real-time RT-PCR (single copy assay),
as reported elsewhere [39]. The optimal HIV-1 RNA detection
threshold was 0.3 copies/ml when 5 to 7 ml of starting plasma was
available. We used a median of 6.5 ml (IQR: 4.6 to 7).
HIV-1 episomal 2LTR DNA circles
The presence of HIV-1 episomal 2LTR DNA circles was
detected by qualitative PCR. To maximize the recovery of 2LTR
DNA circles and overcome the lack of sensitivity of this technique
[8,18,40] enriched 2LTR episomal DNA circles were extracted
selectively from ,5 million PBMC using QIAprep Spin Miniprep
(Qiagen, Valencia, California, USA) following the manufacturer’s
protocol for low-copy-number plasmids, as previously described
[8].
A nested PCR flanking the episomal 2LTR DNA circle junction
was designed. In the first round, 5–20 mL of episomal DNA were
amplified in a 50-mL reaction with the following primers: forward,
59-TAAGATGGGTGGCAAGTGGTCA; and reverse, 59-
TCTACTTGTCCATGCATGGCTT.
The second PCR round was performed using 1 to 2 mL of the
first reaction product as the template and primers spanning the
unique junction formed by ligation of 59 and 39 LTR sequences
(forward, 59-AATCTCTAGCAGTACTGGAAG; reverse, 59-
GCGCTTCAGCAAGCCGAGTCCT). PCR products were an-
alyzed on a 1% agarose gel stained with GelRed (Biotium,
Hayward, California, USA).
Immune activation and lymphocyte subsets
Fresh EDTA anticoagulated whole blood was used to analyze
CD4+ and CD8+ T cell activation with the following antibody
combination: CD3-allophycocyanin (APC)-Cy7, CD4-peridinin
chlorophyll protein complex (PerCP), CD8-phycoerythrin (PE)-
Cy7, CD38-phycoerythrin (PE), and HLA-DR-allophycocyanin
(APC). Lymphocyte subpopulations were defined as naı¨ve
(CD45RA+CCR7+), T central memory (CD45RA-CCR7+,
TCM), T effector memory (CD45RA-CCR7-, TEM), and T
effector memory RA+ (CD45RA+CCR7-, TemRA). To analyze
lymphocyte subsets this antibody combination was used: CD3-
allophycocyanin (APC)-Cy7, CD4-peridinin chlorophyll protein
complex (PerCP), CD8-phycoerythrin (PE)-Cy7, CD45RA- phy-
coerythrin (PE), and CCR7-allophycocyanin (APC), b7-allophy-
cocyanin (APC). Antibodies were from Becton Dickinson (Becton
Dickinson, NJ, USA), and an unstained control was performed for
all samples. Briefly, 100 mL of blood were lysed with 200 ml of
FACS Lysing solution (Becton Dickinson) for 30 min at room
temperature, incubated with the antibodies during 20 min at 4uC,
washed and resuspended in PBS containing 1% azida. Cells were
analyzed in a Gallios flow cytometer (Beckman-Coulter, CA,
USA). At least 15000 CD3+ cells were collected for each sample
and analyzed with Kaluza software (Beckman-Coulter) initially
gating lymphocytes according to morphological parameters. The
gating was always the same between different time points.
Bacterial translocation
Two commercial assays were used to evaluate bacterial
translocation from plasma samples. Plasma bacterial lipopolysac-
charide (LPS) was measured using QCL-1000 Limulus Amebocyte
Lysate (LonzaH, Basel, Switzerland) according to the manufactur-
er’s protocol. This test quantifies endotoxins from the cell wall of
gram-negative bacteria. Plasma sCD14 was quantified using the
QuantikineH Human sCD14 Immunoassay (R&D Systems,
Minneapolis, Minnesota, USA), according to the manufacturer’s
instructions. Samples were run in duplicate in all cases.
Statistical analysis
This is an exploratory pilot study that is trying to prove a
concept. A treatment group of 10 patients has been considered
adequate, based on data from previous studies published by other
authors on the same subject.
Continuous variables were expressed as the median and
interquartile range and discrete variables as percentages. The t
test for independent samples was used to compare normally
distributed continuous variables and the Mann-Whitney test to
compare non-normally distributed continuous variables. Categor-
ical variables were described as proportions. The association
between categorical variables was evaluated using the chi-square
test. A Spearman correlation was used. Statistical analysis was
performed using SPSS software 16.0 (Inc., Chicago, Illinois, USA).
Results
Patient characteristics
The baseline characteristics of the patients are summarized in
table 1. The median age was 46 years and 8 patients were male.
The median baseline CD4+ and CD8+ T-cell counts were 711 and
784 cells/mm3, respectively. All patients were receiving nucleoside
reverse transcriptase inhibitor (NRTI)–containing regimens com-
bined with non-nucleoside reverse transcriptase inhibitors
(NNRTIs) in two cases (22%), with protease inhibitors (PIs) in
five cases (56%), and with a third nucleoside in two cases (22%).
The median duration of ART before study entry was 75 months.
CCR5 Antagonists and HIV-1 Reservoir
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MVC was well tolerated. Two patients interrupted the study
early. Data from these patients were included only until the study
interruption. None of them was included in the final analysis at week
48.One patient, who was coinfected with hepatitis C virus, had a
significant increase in liver enzymes after the visit at week 12; the
other discontinued all antiretroviral drugs due to poor adherence
after the visit at week 12. The remaining patients maintained an
HIV viral load ,50 copies/ml until the end of the study.
Effect of MVC intensification on latent HIV-1 reservoir
The number of latently HIV-1-infected memory CD4+ T cells
decreased after 48 weeks of MVC intensification, although the
difference was not significant (p = 0.068) (figure 2). Three patients
showed a reservoir below the limit of detection before receiving
MVC (figure 2A), and this remained undetectable after 48 weeks
despite a transient increase in two patients. The remaining
patients, all of whom had a quantifiable reservoir at study entry,
showed a decrease in the IUPM after 48 weeks of intensification
(figure 2B) or after 12 weeks of intensification (figure 2C, two
patients who discontinued the study after week 12). A mean
reduction of 1.82 IUPM was found in the 4 patients with
detectable latent reservoir at baseline after 48 weeks of
intensification with MVC.
Effect of MVC intensification on residual viremia
The impact on the cellular reservoir was not associated with
significant changes in residual viremia. At baseline, 8 of the 9
patients had undetectable residual viremia using the single copy
assay. A significant increase in residual viremia was observed after
12 weeks of MVC intensification compared to baseline (p = 0.027).
Afterwards, residual viremia decreased progressively until the end
of the study, with no significant differences compared to baseline
(p = 0.08, table 2).
Effect of MVC intensification on episomal 2LTR DNA
circles
At baseline, episomal 2LTRs DNA circles were undetectable in
all patients. However, at week 12 they were detected in 5 patients
(p = 0.037, compared to baseline) and at week 24 in all 9 patients
(p = 0.012, compared to baseline). At week 48, episomal 2LTR
DNA circles were again undetectable in all patients (table 2).
Effect of MVC intensification on T-cell activation
The level of activation of CD4+ T cells decreased significantly
after 12, 24, and 36 weeks of MVC intensification (p = 0.028,
p = 0.027, and p = 0.028, respectively), only to increase after 48
weeks, although the difference with baseline was not significant
(p = 0.6) (figure 3). Compared to HIV-negative subjects, CD4+ T-
cell activation at baseline was significantly higher (p,0.001), with
no significant differences at weeks 12 and 24 (p = 0.950 and
p = 0.181, respectively).
The level of activation of CD8+ T cells also decreased
significantly after 12 weeks and until the end of the study
(p = 0.043, p = 0.025, p = 0.028, and p = 0.046, at weeks 12, 24,
36, and 48, respectively) (figure 3). The level of cell activation at
baseline was higher than in the HIV-negative subjects (p = 0.001).
Only at week 48 was this difference not significant compared to
the HIV-negative group (p = 0.181).
Effect of MVC intensification on T-cell subsets
No differences in the absolute number or percentage of CD4+
or CD8+ T cells were found during follow-up. A significant
increase in CD8+ effector memory and TemRA T cell count was
found during the first 24 and 36 weeks after MVC intensification,
respectively. Thereafter, the differences compared to baseline were
not significant (figure 4). On the other hand, a significant decrease
in CD8+ central memory T cells was observed at week 12
(p = 0.002). The level of CD8+ naive T cells was similar during
follow-up (p.0.05 at all time points). No significant differences
were observed in any CD4+ T cell subsets during follow-up (data
not shown).
The proportion of CD8+ naı¨ve and memory T cells expressing a
b7 receptor significantly increased after 12 weeks of intensification
(p = 0.037 and p = 0.007, respectively) (figure 5A and 5B
respectively). The expression of b7 receptor also increased in
activated CD8+ T cells at week 12 compared to baseline
(p = 0.046), and a trend was observed during the rest of the follow
up (figure 5C).
Effect of MVC intensification on bacterial translocation
A significant increase in sCD14 level was observed after 24, 36
and 48 weeks of intensification with MVC compared to baseline
(p = 0.015, p = 0.028 and p = 0.028, respectively) (figure 6). These
Table 1. Baseline characteristics of the patients.
Patient ID Age (years) Gender
Risk
Factors
Viral load
(copies/ml)
CD4 count
(cells/mm3)
CD8 count
(cells/mm3)
Duration of
ART (months)
Current ART
regimen
MVC
intensification
(mg/BID)
MVC 1 49 M IDU ,50 1169 683 124 ddI+3TC+NVP 300
MVC 2 47 M MSM ,50 486 673 75 FTC+TDF+ATV/r 150
MVC 3 46 M IDU ,50 796 650 78 3TC+ABC+ATV 150
MVC 4 46 F HSx ,50 534 784 57 AZT+3TC+ABC 300
MVC 5 45 M IDU ,50 728 639 142 AZT+3TC+ABC 300
MVC 6 58 M MSM ,50 787 1109 144 FTC+TDF+LOP/r 150
MVC 7 32 M MSM ,50 694 1608 50 FTC+TDF+ATV/r 150
MVC 8 30 M MSM ,50 589 1064 42 FTC+TDF+EFV 600
MVC 9 30 M MSM ,50 1241 1414 38 TC+TDF+LOP/r 150
Median [IQR] 46 [31–48] - - ,50 711 [547–793] 784 [673–1109] 75 [38–144] - -
ddI: didanosine; NVP: nevirapine; FTC: emtricitabine; TDF: tenofovir; ATV/r: atazanavir/boosted with ritonavir; ABC: abacavir; AZT: zidovudine; LOP/r: lopinavir/boosted
with ritonavir; EFV: efavirenz; F: Female; M: Male; HSx, Heterosexual; MSM: men who have sex with men.
doi:10.1371/journal.pone.0027864.t001
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levels were significantly lower than those of naive HIV-1-infected
patients at all time points. LPS levels were also higher at weeks 24,
36, and 48 of intensification than at baseline (p = 0.006, p = 0.006,
and p = 0.021, respectively) (figure 6). The level of LPS at baseline
was significantly lower that that of treatment-naive HIV-1-infected
patients; during follow-up, these levels were no different from
those of the treatment-naive patients.
A significant direct correlation was found between sCD14 levels
and LPS levels at baseline (p = 0.035, r = 0.743) while a similar
trend was observed during the rest of the follow up. Furthermore,
Figure 2. Effect of MVC intensification on HIV-1 latently infected memory CD4+ T cells. (a) Patients who had a latent reservoir below the
limit of detection at baseline, and remained undetectable after 48 weeks of intensification. (b) Patients with quantifiable latent reservoir at baseline,
and decreased after 48 weeks of intensification, (c) patients with quantifiable latent reservoir at baseline but discontinuated the study after w12.
Square symbols: detection limit of 0.12 IUPM. Diamond symbols: detection limit of 0.023 IUPM. Open symbols: under the limit of detection.
doi:10.1371/journal.pone.0027864.g002
Table 2. Effect of MVC intensification on residual viremia and episomal DNA circles.
Patient SCA Episomal 2LTR DNA
ID Baseline w12 w24 w36 w48 Baseline w12 w24 w36 w48
MVC 1 0.3 S.F. S.F. ,0.3 ,0.3 - + + - -
MVC 2 ,0.3 ,0.3 N.D. N.D. N.D. - + N.D. N.D. N.D.
MVC 3 ,0.3 SF ,0.5 0.5 - - + - -
MVC 4 ,0.3 9.2 ,0.4 ,0.3 ,0.3 - - + - -
MVC 5 ,0.3 1.0 ,0.5 ,0.3 2.2 - - + - -
MVC 6 ,0.3 3.0 3.0 1.1 3.3 - + + - -
MVC 7 ,0.6 7.0 ,0.5 ,0.5 ,0.5 - - + + -
MVC 8 ,0.4 0.5 4.6 ,0.5 3.7 - + + - -
MVC 9 ,2.0 1.0 N.D. N.D. N.D. - + N.D. N.D. N.D.
Median 0[0–0] 1[0.5–7] 0[0–3.4] 0[0–0.2] 0.5[0–3.3]
p * 0.027 0.1 0.6 0.08 0.037 0.012
SCA: Single copy assay; S.F.: Standard failure; N.D.: Not determined; *: Statistical significance compared to baseline (significance p,0.05).
doi:10.1371/journal.pone.0027864.t002
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Figure 3. Immune activation during MVC intensification. CD4+ and CD8+ T cell activation of the patients during the follow up is shown. A
group of HIV-1 negative individuals are also shown.
doi:10.1371/journal.pone.0027864.g003
Figure 4. CD8+ T cell subpopulations after MVC intensification. The proportion of naı¨ve, central memory (TCM), effector memory (TEM), and
effector memory RA+ (TemRA) cells is shown.
doi:10.1371/journal.pone.0027864.g004
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the LPS level correlated directly with both the proportion of CD4+
T cells expressing a b7 receptor and the level of naive CD4+ T
cells expressing b7 receptor at week 24 (p = 0.047, r = 0.817).
Similarly, the level of LPS at week 36 correlated directly with that
of CD8+ effector memory T cells (p = 0.045, r = 0.818).
Discussion
In this pilot study, intensification of treatment with MVC in
patients chronically infected with HIV-1 receiving successful long-
term ART was associated with a trend to an accelerated decay in
the pool of latently infected CD4+ T cells. No impact on residual
viremia was observed.
Intensification of successful antiretroviral therapy has been
explored in two different ways. Some studies have evaluated its
role for clinical purposes, that is, to achieve better virological
control or a greater increase in CD4+ T-cell counts, or, more
recently, to reduce immune activation. With the exception of one
study that showed a decrease in HIV RNA levels after abacavir
intensification, none of the studies has been able to show
significant improvements with intensified therapy compared to
the standard three-drug regimens [11,12,14–17,41]. As a conse-
quence, most clinicians feel that no further research in this
direction is necessary. Other studies have evaluated intensification
as a strategy to help to eradicate HIV. The rationale for this
approach is that suppression of putative replication could reduce
residual viremia and replenishment of cellular reservoirs leading to
a decrease in the total latent reservoir [8–18,41]. The results of all
the studies are uniform in that no single group has shown a
significant reduction in plasma HIV RNA as a result of
intensification. This finding could be interpreted as confirmation
of the lack of residual viral replication, thus supporting the
hypothesis that residual viremia is the result of viral release from
stable reservoirs and not the consequence of new rounds of viral
replication [5–7]. An alternative hypothesis would be that the
effect of intensification takes place mainly outside plasma sites and,
therefore, the measurement of plasma viral load only could not
detect this effect. Some of the studies that included measurements
other than plasma HIV RNA seem to support this hypothesis [42–
44].
We observed a reduction in the size of the latent reservoir after
intensification of treatment with MVC, although this reduction
was not significant, probably due to the small sample size. This
finding is consistent with other studies that included patients with
different baseline characteristics [22,23], although some authors
do not support it [24]. The decline in the latent reservoir that we
Figure 5. Proportion of CD8+ T cells expressing b7 receptor. A) naı¨ve T cells, B) memory T cells, and C) activated T cells.
doi:10.1371/journal.pone.0027864.g005
Figure 6. Bacterial translocation. Levels of sCD14 and LPS during the follow up are shown. The levels of a group of HIV-1 positive naı¨ve for ART
are also included.
doi:10.1371/journal.pone.0027864.g006
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found does not appear to be secondary to a decrease in residual
viral replication in plasma, since there were no detectable changes
in the measurements of residual viremia. It has been suggested that
a dilutional effect could account for the reduction observed, but
the lack of an increase in the absolute count and the percentage of
both CD8+ and CD4+ T cells strongly argues against this
possibility.
Other findings in our study may help explain the effect on the
latent reservoir. Unexpectedly, 2LTR DNA circles were transient-
ly detectable during MVC intensification. Due to its mechanism of
action, MVC is not expected to increase 2LTR DNA circles, even
when inhibiting persistent viral replication. The increase in levels
of this marker suggests that treatment with MVC in patients with
undetectable viral load may induce viral replication. Preclinical
studies showed that MVC had no agonistic activity on activated
CD4+ T cells and, therefore, could not induce viral replication
[32]. Later reports, however, have shown that the possibility of
acting as a partial agonist on CCR5 could be dependent on cell
type [45]. Therefore, MVC could activate CCR5 in resting CD4+
T cells and, through intracellular signalling, increase transcrip-
tional activation of the latent virus. As an alternative hypothesis,
CCR5 blockade by MVC could lead natural ligands or
chemokines to bind to other receptors and induce latent HIV
transcriptional activation through distinct signalling pathways.
Both hypotheses would be consistent with the reduced number of
latently infected memory T cells found in this study, the transient
increase in the number of copies of HIV RNA seen in some
patients, and the increased bacterial translocation plus migration
of a4b7 cells to the gut. This possibility is further supported by the
increased immune activation in intestinal tissue biopsies that was
observed in another MVC intensification study [46]. Finally,
trafficking of cells to peripheral blood from some other
compartment cannot be discarded to explain some of the results,
including the increase in 2 LTR circles.
Neither of the above hypotheses can account for the diminished
immune activation that we detected. MVC has been shown to
decrease immune activation in clinical trials, and it could be
assumed that a different mechanism drives the impact on immune
activation [47]. The decrease in immune activation does not
correlate with a decrease in bacterial translocation, which in fact
increased during the study, thus supporting increased viral
replication and activation in the intestine resulting from the
release of proinflammatory cytokines [48].
The transient increase in TEM and TemRA CD8+ T cell counts
parallels the increase in bacterial translocation. These increments
are balanced by a transient decrease in central memory CD8+ T cell
counts, while naive CD8+ T cell levels remain stable [49]. In
addition, the finding of increased b7 receptor levels on CD8+ T cells
and especially on activated CD8 T cells support the idea of
migration of these cells to the intestine, where bacterial translocation
takes place. This migration of activated cells to the gut could
account for the reduced immune activation observed in the
periphery. In this sense, immune events detected in peripheral
blood may not reflect what takes place in the intestine, as is the case
for the huge CD4+ T-cell destruction that occurs in the intestine of
the SIV rhesus macaque during acute infection, which is not
reflected in lymph nodes or peripheral blood [50].
Our work has a series of limitations. First, it is a pilot study with
a small sample size, thus limiting the strength of the conclusions.
Second, no control group was included. The study was designed as
a proof of concept with no guarantee of any spontaneous effect in
the sample. Finally, the methodological tools used for the different
measurements and their interpretations are still imperfect.
In summary, our study shows positive effects of MVC
intensification on latently HIV-1-infected CD4+ T cells. These
effects are not reflected in reduced residual plasma viremia and
may be associated with the activity of the drug in an anatomical
reservoir, most likely the intestine. The mechanism by which
MVC decrease the HIV-1 reservoir is under investigation. The
decrease we observed, however, is by no means large enough to
eradicate HIV. New therapeutic strategies, probably based on
anti-latency drugs, are necessary to eradicate viral reservoirs. In
this sense, complete inhibition of viral replication at all sites can be
presumed to be necessary before these new treatment strategies
can be applied. The exact role of treatment intensification in
eradication remains undefined, and a large, comparative trial with
adequate methodology is needed to provide a definitive answer to
this relevant question.
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